摘要
目的:借助网络药理学的方法探讨化湿败毒方治疗新型冠状病毒肺炎(COVID-19)的作用机制。方法:通过TCMSP数据库检索化湿败毒方中药物含有的化合物,筛选其活性成分及其作用靶点并通过Uniprot数据库进行蛋白标准化处理,Cytoscape 3.7.2软件构建"药物-活性成分-靶点"网路;通过GeneCards数据库筛选与COVID-19相关的靶标,STRING数据库与DAVID数据库分别进行PPI网络的构建与分析,GO分析和KEGG富集分析(P<0.05)。结果:化湿败毒方"药物-活性成分-靶点"网络共包括176个成分和149个靶点,关键靶点涉及AR、ESR1、PTGS2、PPARG、NOS2等;COVID-19相关靶标251个;GO功能富集分析得到179条生物过程,主要涉及炎症反应、细胞凋亡的调控、免疫反应等,获得82条KEGG相关信号通路,涉及HIF-1、TNF、小细胞肺癌、非小细胞肺癌、结核、PI3K-Akt、NF-κB、MAPK等信号通路。结论:化湿败毒方可能通过作用于AR、ESR1、PTGS2、PPARG、NOS2等靶点调控机体的免疫、炎症反应来治疗COVID-19,是多成分联合多靶点、多途径相互作用的结果。
Objective:To explore novel coronavirus pneumonia(COVID-19)by the method of network pharmacology.Methods:The compounds contained in the Huashi Baidu Formula were searched by TCMSP database,the active components and their action targets were screened,and the proteins were standardized by Uniprot database,and the“drug-active ingredient-target”network was constructed by Cytoscape3.7.2 software.The targets related to COVID-19 were screened by GeneCards database.STRING database and DAVID database were used to construct and analyze PPI network,GO analysis and KEGG enrichment analysis(P<0.05).Results:The“drug-active ingredient-target”network of Huashi Baidu Formula consists of 176 components and 149 targets,including AR,ESR1,PTGS2,PPARG,NOS2 etc.,and 251 targets related to COVID-19.GO functional enrichment analysis showed that there were 179 biological processes,mainly related to inflammation,regulation of apoptosis and immune response,and 82 KEGG related signaling pathways were obtained,including HIF-1,TNF,small cell lung cancer,non-small cell lung cancer,tuberculosis,PI3K-Akt,NF-κB,MAPK etc.Conclusion:Huashi Baidu Formula may regulate the immune and inflammatory response of the body by acting on AR,ESR1,PTGS2,PPARG,NOS2 and other targets,which is the result of multi-component,multi-target and multi-channel interaction.
作者
刘源
刘金豹
彭伟
LIU Yuan;LIU Jin-bao;PENG Wei(Shandong University of traditional Chinese medicine,Jinan Shandong 250014,China;Affiliated Hospital of Shandong University of traditional Chinese Medicine,Jinan Shandong 250014,China)
出处
《海南医学院学报》
CAS
2020年第11期804-813,共10页
Journal of Hainan Medical University
基金
山东省重点研发计划(2016GSF202022)。
